The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Ujala Bokary at 847.570.1783
Open to Enrollment: Yes

ABI-007-NSCL-005: Safety and efficacy of nab ® -paclitaxel (Abraxane ®) in combination with carboplatin with carboplatin as first line treatment in elderly subjects with advanced non-small cell lung cancer (NSCLC): A Phase IV, randomized, open-label, multicenter study
Aims: This study will compare two schedules of this combination in patients who are at least 70 years old. The purpose of this study is to find out which nab-paclitaxel/carboplatin schedule is better tolerated and to compare efficacy between the two schedules.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-256
Sponsor: Celgene Corporation
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study.
Diagnosis: Squamous Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-415
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A Prospective Randomized, Controlled, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thorascopic Lobectomies
Aims: The study is comparing rates of hemostatic interventions between FDA approved ECHELON FLEX Powered Vascular Stapler with Advanced Placement Tip to the leading Standard of Care vascular stapler used in video-assissted Thorascopic Surgery (VATS) Lobectomy. This study will be recruiting patients with suspected or confirmed stage IA to stage IIIA Non-Small Cell Lung Cancer who will be receiving a lobectomy.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH15-205
Sponsor: Ethicon Endo-Surgery
Contact: For more information, interested participants may contact Patricia Park at 847.570.1675, ppark@northshore.org
Open to Enrollment: Yes

E4512: Testing the Addition of Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition of crizotinib may help prevent your cancer from returning, but it could also cause side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to determine if patietns iwth Non-Small Cell Lung Cancer (NSCLC) have a mutation (abnormal change) in the DNA or their tumor and if so, which one.  The genetic mutations which are being assessed are: EGFR, ALK, an dPD-L1.  Not all lung tumors have the changes in genes.  The study will lead into two optional treatment trials which will use specific drugs to target these genes as well as tumors without mutations.  Tissue from the tumor removed at the time of surgery is sent to a national laboratory to be analyzed and compared to local results. 
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stage IB, II, IIIA
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A Multicenter, Randomized Trial of Esophagetcomy and Cervical Esophagogastrostomy With (Two-stage) or Without (One-stage) Prior Ischemic Gastric Conditioning by Laparoscopic Ligation of Left Gastric and Short Gastric Arteries
Aims: The study aims to determine if ischemic gastric preconditioning by cutting part of the blood supply to the stomach several days before the esophagectomy procedure minimizes side effects. It will also examine if there is a difference in the quality of life (QOL) of patients in two arms of the study as assessed by validated questionnaires.
Diagnosis: Surgical candidates for esophageal cancer
Principal Investigator: 
Ki Wan Kim, MD
IRB Approval Number: 
EH15-175
Sponsor:
 NorthShore University HealthSystem
Contact: Interested patients may contact Jen Jaffe, MPH, CCRP at 847.570.2803, jjaffe@northshore.org or Peter Frost at 847.570.2935, pfrost@northshore.org

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Aims: The purpose of this research study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (and investigational drug).
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Ki Wan Kim, MD 
IRB Approval Number: EH15-123
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A221303: Randomized Study of Early Palliative Care Integreated with Standard Oncology Care Versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Aims: The purpose of this research study is to see whether patients who receive care from palliative care doctors and nurses at an earlier time in their disease, along with their regular cancer care, will experience less emotional and physical issues from their cancer.
Diagnosis: Incurable Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH15-215
Sponsor: Alliance
Contact: Interested patients should contact research nurse Susan Greve, RN at 847.570.1183
Open to Enrollment: Yes

Best Practive in VATS Lobectomy and Segmentectomy for Lung Cancer: A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Aims: This is a multi-center study which will be conducted at seven sites. The purpose of this study is to establish a database for doing data and cost analysis of the workup, early treatment and follow-up of patients who have VATS lobectomy or segmentectomy for lung cancer.
Diagnosis: Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH13-155
Sponsor: Ethicon Endo Surgery
Contact: Interested participants may contact Ujala Bokhary, MBBS, CCRP at 847.570.1783, ubokhary@northshore.org
Open to Enrollment
: Yes

Mirati: 265-109: Phase 2, Parallel-Arm Study of GCD265 in Patients wtih Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Facto
Aims: The purpose of this study is to see if you have the changes in tumor genes that are targeted by this drug, MGCD265. If you have the changes, then you will be given this drug and we will be assessing side effecte, efficacy and how this drug is absorbed and eliminated from the body.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH16-105
Sponsor: Mirati Therapeutics
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment: Yes

AstraZeneca: D4191C00004: A Phase III, Open-Label, Randomized, Multi-centre, International Study of MEDI4735, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherarpy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARTIC) Study
Aims:
The main purpose of this study is to determine if the following drugs or combinations of MEDI4736 and/or Tremelimumab respond better  compared to Investigator's choice of standard chemotherapy in subjects with metastatic or advanced non-small cell lung cancer (NSCLC).
Diagnosis: 
Non-Small Cell Lung Cancer
Principal Investigator:
Thomas Hensing, MD
IRB Approval Number:
EH15-070
Sponsor:
AstraZeneca
Contact:
Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment:
Yes 

AFT-09: Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy naive stage IV Non-Small Cell Lung Cancer
Aims: The purpose of this study is to see  the administration of standard platinum-based chemotherapy before pembrolizumab (immune therapy) would improve response rates compared to pembrolizumab alone before chemotherapy.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH16-169
Sponsor: Mirati Therapeutics
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment: Yes

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Aims:
The purpose of this research study is to find out whether treatment with nivolumab (also known as OPDIVO), a type of immunotherapy will result in improved survival over placebo for patients with STage IB-IIIA NSCLC following complete resection and standard post-operative therapy.  This study is the treatment trial linked to A151216 Alchemist trial withere the tissue is sent for  determiniation of gene mutations post operatively.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stages IB, II, IIIA
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH16-268
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512, cfredia
Open to Enrollment: Yes